文献速递神经肿瘤

液体活检鉴别恶性脑肿瘤真性进展与放射性坏死及假性进展的临床效用

Clinical utility of liquid biopsy in distinguishing true progression from radiation necrosis and pseudoprogression in malignant brain tumor.
PubMed 文献 · J Neurooncol · 2026-05-25

该系统综述检索PubMed、Embase、Scopus和Cochrane数据库,共纳入11项研究,评估液体活检生物标志物鉴别真性肿瘤进展与假性进展(PsP)及放射性坏死(RN)的效能。多种标志物在组间显示统计学显著差异,但证据受小样本、方法异质性和缺乏标准化诊断标准限制。

要点

  • 液体活检标志物在鉴别RN、PsP与肿瘤复发中显示统计学显著差异。
  • 复合指数如DR-VNN2指数(DVI)和坏死预测指数(NPI)有改善诊断分化的潜力。
  • 现有证据受小样本、方法异质性和缺乏标准化诊断标准限制,需更大前瞻性研究验证。

核心结论

  • 液体活检生物标志物在鉴别放射性坏死和假性进展与肿瘤复发方面显示前景,但证据受小样本、方法异质性和缺乏标准化诊断标准限制。

研究设计与样本

  • 系统综述检索PubMed、Embase、Scopus和Cochrane数据库,初检964条记录,去除157条重复后筛选807项研究,最终11项研究符合纳入标准。

主要发现

  • 研究的液体活检标志物包括免疫细胞标志物(如HLA-DRneg/low和VNN2+ CD14+单核髓源性抑制细胞)、免疫相关蛋白(如CXCL11和MUC-16)、循环肿瘤细胞、游离DNA、线粒体DNA、B1-SINE元件、微囊泡和RNA分析物。
  • 血浆是最常用的生物流体,尿液和脑脊液评估有限。
  • 多种标志物在放射性坏死、假性进展和肿瘤复发间显示统计学显著差异,但诊断性能指标报告不一致。

关键数值与推荐

  • 复合指数如DR-VNN2指数(DVI)和坏死预测指数(NPI)显示改善诊断分化的潜力。

临床怎么用

  • 液体活检作为非侵入性方法,有望辅助鉴别放射性坏死、假性进展与肿瘤复发,但当前证据尚不足以确立标准化临床应用。

局限性

  • 纳入研究样本量小、方法异质性大、缺乏标准化诊断标准,且诊断性能指标报告不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Distinguishing true tumor progression from pseudoprogression (PsP) and radiation necrosis (RN) following radiotherapy or radiosurgery for intracranial tumors remains a significant clinical challenge. Conventional imaging modalities, including MRI and PET, often lack sufficient diagnostic accuracy, while histopathological confirmation, although definitive, is invasive and not always feasible. Liquid biopsy (LB) has emerged as a promising noninvasive diagnostic approach. METHODS: A systematic review was conducted across PubMed, Embase, Scopus, and Cochrane databases. A total of 964 records were identified, including PubMed (n = 322), Embase (n = 280), Scopus (n = 297), and Cochrane (n = 65), along with three clinical trials identified from trial registers. After removal of 157 duplicates using Covidence, 807 studies were screened by title and abstract. Of these, 749 were excluded, and 58 articles underwent full-text review. Ultimately, 11 studies met the inclusion criteria and were included in the analysis. RESULTS: A diverse range of LB-based biomarkers has been investigated, including immune cell-based markers (e.g., HLA-DRneg/low and VNN2+ CD14+ monocytic myeloid-derived suppressor cells), immune-related proteins (e.g., CXCL11 and MUC-16), circulating tumor cells, cell-free DNA, mitochondrial DNA, B1-SINE elements, microvesicles, and RNA analytes. Plasma was the most used biofluid, with limited evaluation of urine and cerebrospinal fluid. Analytical techniques varied widely, including flow cytometry, PCR-based assays, immunostaining-FISH, and multiplex protein platforms. Several biomarkers showed statistically significant differences among RN, PsP, and tumor recurrence; however, these findings were largely derived from small, heterogeneous cohorts with inconsistent reporting of diagnostic performance metrics. Composite indices, such as the DR-VNN2 index (DVI) and the Necrosis Prediction Index (NPI), showed potential for improving diagnostic differentiation. CONCLUSIONS: LB-based biomarkers show promise for differentiating RN and PsP from tumor recurrence; however, current evidence is limited by small sample sizes, methodological heterogeneity, and lack of standardized diagnostic criteria. Larger prospective studies and validation of composite biomarker models are required to establish their clinical utility. CLINICAL TRIAL NUMBER: Not Applicable.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Izhar M, Hori YS, Lam FC, et al. Clinical utility of liquid biopsy in distinguishing true progression from radiation necrosis and pseudoprogression in malignant brain tumor. J Neurooncol. 2026. PMID: 42185659. doi:10.1007/s11060-026-05618-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。